Business Context and Reporting Period
Company: Voyager Therapeutics, Inc. (VYGR)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Voyager is a biotechnology company focused on developing genetic medicines for neurological diseases, including Alzheimer's disease (AD), Friedreich's ataxia, and Parkinson's disease. The company utilizes its proprietary TRACERTM AAV capsid discovery platform and Voyager NeuroShuttleTM non-viral delivery platform. It has no product revenue and relies on collaboration agreements and equity financing.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Collaboration Revenue | $5,758 | $11,673 |
| Total Operating Expenses | $62,420 | $82,991 |
| Net Loss | $(52,410) | $(64,403) |
| Net Loss Per Share (Basic & Diluted) | $(0.87) | $(1.10) |
| Cash, Cash Equivalents, and Marketable Securities | $148,800 | $191,029 |
| Accumulated Deficit | $(498,315) | $(390,587) |
| Net Cash Used in Operating Activities | $(59,261) | $(71,156) |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by approximately 51% year-over-year (from $11.7M to $5.8M). This was driven by lower recognition from the 2023 Neurocrine Collaboration Agreement and the 2019 Neurocrine Collaboration Agreement, partially offset by revenue from the 2023 Novartis Collaboration Agreement.
- Expense Reduction: Total operating expenses decreased by $20.6 million (25%). Research and Development (R&D) expenses dropped $16.2 million, and General and Administrative (G&A) expenses dropped $4.4 million. Management attributes these reductions to lower headcount following 2025 restructuring, reduced spend on the VY7523 program (enrollment completed), and the discontinuation of the SOD1 program.
- Improved Loss Profile: Net loss improved by $12.0 million year-over-year, primarily due to the significant reduction in operating expenses.
- Capital Raise: The company raised $5.7 million in net proceeds through its At-The-Market (ATM) facility during the six months ended June 30, 2026.
Guidance, Outlook, and Risks
Outlook and Milestones
- Liquidity: As of June 30, 2026, the company held $148.8 million in cash and marketable securities. Management expects these resources, combined with collaboration reimbursements and interest income, to fund operations into 2028.
- Clinical Pipeline:
- VY1706 (Tau-silencing gene therapy): FDA cleared the IND in Q2 2026. Dosing in a Phase 1 trial is expected to begin in Q4 2026. Initial acute safety data is anticipated in early 2027.
- VY7523 (Anti-tau antibody): Phase 1 multiple ascending dose (MAD) trial enrollment completed in Q4 2025. Initial tau PET imaging efficacy data is expected in Q4 2026.
- Collaborations: The company retains opt-in rights for programs with Neurocrine (FA and GBA1) and Transition Bio (ALS/FTD). Novartis partially terminated the 2022 Option and License Agreement regarding two targets in February 2026, reverting IP rights to Voyager.
Risks and Contingencies
- Capital Requirements: The company has a history of losses and expects to continue incurring significant expenses. It will require additional financing to achieve its objectives. Failure to raise capital could force delays or termination of programs.
- Development Risks: Clinical trials may fail to demonstrate safety or efficacy. Regulatory approvals are uncertain.
- Collaboration Dependence: Future revenue is heavily dependent on milestone payments and royalties from partners (Neurocrine, Novartis, Alexion), which are contingent on successful development and commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $148.8M cash balance against the projected burn rate into 2028, considering the upcoming costs of the VY1706 Phase 1 trial.
- Revenue Recognition: Review the specific terms of the Neurocrine and Novartis agreements to understand the timing and certainty of future milestone payments versus the current decline in recognized revenue.
- Program Prioritization: Confirm the strategic rationale behind the discontinuation of the SOD1 program and the reduced spend on VY7523 post-enrollment.
- Novartis Termination Impact: Assess the financial impact of the partial termination of the 2022 Novartis agreement and the reversion of IP rights.
- ATM Facility Status: Monitor the remaining capacity ($94.1M) and utilization of the ATM facility as a primary source of near-term liquidity.